Avacta appoints BBI Options as manufacturing companion for the speedy SARS-CoV-2 antigen check being developed with Cytiva Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is…
- Sunday, September 24, 2023
Avacta appoints BBI Options as manufacturing companion for the speedy SARS-CoV-2 antigen check being developed with Cytiva Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is…